Sustainability Outside the Box - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sustainability Outside the Box
Drugmakers and packagers are pursuing various initiatives to reduce their carbon footprints. This article contains bonus material.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 40-44

Recycled content

Levels of recycled content are increasing in many packaging formats, particularly for fiber-based packaging, such as corrugated cases, and film and containers made of polyethylene terephthalate (PET). In fact, GSK has switched from a PVC clamshell to a recycled PET (rPET) clamshell for Abreva. The change cuts carbon-dioxide emissions by 25–52 g/pack.

PET films with recycled content fit numerous applications and are compatible with radio-frequency sealing or heat sealing. Designed to contain a minimum of 35% or 50% postconsumer recycled (PCR) content derived from bottles, respectively, the films are suitable for thermoformed packaging, including clamshells, blisters, and trays (Pentaform SmartCycle films, Klöckner Pentaplast Group).

With rising demand, especially from the beverage industry, the supply of food-grade rPET is growing rapidly. New capacity for food-grade rPET is becoming available in North America, Europe, and Asia. A vertically integrated container maker is expanding its recycling facility to produce ultraclean rPET from PCR material so it can increase rPET levels in its food-grade containers. The expansion will also help the company double its worldwide recycling capability to 10 billion bottles per year by 2016 (Clean Tech recycling facility, Plastipak Packaging).

The expansion of a recycling operation in the United Kingdom will more than double production of food-grade rPET in that country and help Coca-Cola Enterprises increase recycled content to 25% in all its PET packaging in Great Britain by 2012 (ECO Plastics).

The expansion of another European recycling plant will increase its rPET capacity from 25,000 to 35,000 metric tons and nearly double the number of bottles diverted from landfills each year. The vertically integrated plant in France also produces preforms (Artenius PET Packaging Europe).

A plant under construction in Vietnam will recycle 1.5 billion PET bottles per year into food-grade rPET. Although configured primarily for bottle-to-bottle applications, the facility also can produce recycled resin for fiber or carpet (Thanh Tai Gas).

Renewable materials

Although bioplastics, such as polylactic acid and microorganism-generated polyhydroxyalkanoates (PHA), receive considerable attention from package designers and specifiers, much interest in biopolymers has shifted to traditional resins such as high-density polyethylene (HDPE) and PET made from plant-derived feedstocks. These replacements are chemically identical to their petroleum-based counterparts and are recyclable through existing postconsumer collection streams.

In fact, bio-based commodity plastics are forecast to overtake biodegradable materials globally, especially for packaging applications. "Our market study shows that biobased commodity plastics, with a total of around 1 million [metric] tons, will make up the majority of production capacity in 2015," reports Hans-Josef Endres, professor of engineering and biotechnology at the University of Applied Sciences and Arts of Hanover, Germany. Of a total market of 1.7 million metric tons in 2015, traditional biodegradable bioplastics will account for 0.7 million metric tons (3).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here